PMC:7377212 / 20400-20655 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T163","span":{"begin":43,"end":59},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T164","span":{"begin":60,"end":65},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T165","span":{"begin":96,"end":111},"obj":"PR:000001137"},{"id":"T166","span":{"begin":114,"end":125},"obj":"DG_35"},{"id":"T167","span":{"begin":132,"end":145},"obj":"PR:000001393"},{"id":"T168","span":{"begin":164,"end":174},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T169","span":{"begin":208,"end":216},"obj":"SP_7"},{"id":"T162","span":{"begin":12,"end":19},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T69247","span":{"begin":58,"end":73},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T20303","span":{"begin":74,"end":79},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T81754","span":{"begin":110,"end":116},"obj":"PR:000001137"},{"id":"T16643","span":{"begin":119,"end":130},"obj":"DG_35"},{"id":"T55627","span":{"begin":137,"end":140},"obj":"PR:000001393"},{"id":"T41646","span":{"begin":165,"end":175},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T67111","span":{"begin":209,"end":216},"obj":"SP_7"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T51","span":{"begin":96,"end":107},"obj":"Body_part"},{"id":"T52","span":{"begin":132,"end":145},"obj":"Body_part"}],"attributes":[{"id":"A51","pred":"fma_id","subj":"T51","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A52","pred":"fma_id","subj":"T52","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-PubTator","denotations":[{"id":"601","span":{"begin":96,"end":111},"obj":"Gene"},{"id":"603","span":{"begin":238,"end":246},"obj":"Species"},{"id":"608","span":{"begin":114,"end":125},"obj":"Chemical"},{"id":"609","span":{"begin":208,"end":216},"obj":"Disease"}],"attributes":[{"id":"A601","pred":"tao:has_database_id","subj":"601","obj":"Gene:3557"},{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"Tax:9606"},{"id":"A608","pred":"tao:has_database_id","subj":"608","obj":"MESH:C502936"},{"id":"A609","pred":"tao:has_database_id","subj":"609","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T210","span":{"begin":0,"end":12},"obj":"Disease"},{"id":"T211","span":{"begin":208,"end":216},"obj":"Disease"},{"id":"T212","span":{"begin":250,"end":254},"obj":"Disease"}],"attributes":[{"id":"A210","pred":"mondo_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/MONDO_0019121"},{"id":"A211","pred":"mondo_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A212","pred":"mondo_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T177","span":{"begin":132,"end":145},"obj":"http://purl.obolibrary.org/obo/PR_000001393"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T303","span":{"begin":60,"end":65},"obj":"Chemical"},{"id":"T304","span":{"begin":114,"end":125},"obj":"Chemical"},{"id":"T305","span":{"begin":164,"end":174},"obj":"Chemical"}],"attributes":[{"id":"A303","pred":"chebi_id","subj":"T303","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A304","pred":"chebi_id","subj":"T304","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A305","pred":"chebi_id","subj":"T305","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T4","span":{"begin":157,"end":174},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}

{"project":"LitCovid-sentences","denotations":[{"id":"T104","span":{"begin":0,"end":255},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Pneumocystis pneumonia.Finally, the use of immunomodulatory drugs such as anakinra (recombinant interleukin-1Ra), tocilizumab (anti-interleukin-6) and Janus kinase inhibitors, currently undergoing trials for COVID-19, may also predispose patients to CAPA."}